Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Johnson & Johnson Faces Shareholder Activism Over Human Rights and Executive Pay Proposals

March 20, 2025
Mark Dickinson, the leader of Johnson & Johnson Neurovascular, is leaving the company, according to sources. Dickinson's departure comes at a crucial time for the company as it faces growing shareholder activism over human rights and executive pay proposals.

In recent months, Johnson & Johnson has been criticized for its alleged involvement in human rights violations and unethical business practices. Shareholders are now demanding accountability and transparency from the company.

In addition to the human rights concerns, Johnson & Johnson is also under scrutiny for its executive pay structure. Shareholders argue that the compensation packages of top executives are excessive and not aligned with the company's performance.

Meanwhile, an AI imaging firm has accused Johnson & Johnson of stealing its technology. The firm claims that Johnson & Johnson used its AI imaging technology without permission and is seeking legal action. Testimony for the case began on Monday.

With the increasing challenges it is facing, Johnson & Johnson could be a risky investment. However, experts from Stocks Prognosis recommend seeking professional advice before making any investment decisions.

Investors who are considering buying Johnson & Johnson shares should be aware of the ongoing controversies and potential risks associated with the company. It is important to stay informed and thoroughly analyze the situation before making any financial commitments.
If you want to leave a comment, then you need Login or Register





Other data for JNJ

Related data

JNJJuly 14, 2025Johnson & Johnson Innovates with New Product Launches  ~1 min.

Johnson & Johnson, a leading pharmaceutical company, continues to make waves in the industry with its latest submission of sNDA for the schizophrenia drug CAPLYTA to the FDA....

JNJMay 25, 2025Revolutionary Innovation: JNJ Johnson & Johnson Leads the Medical Industry with Groundbreaking Technology  ~1 min.

Johnson & Johnson, the renowned medical technology company, continues to be at the forefront of innovation in the industry....

JNJMarch 21, 2025Johnson & Johnson Neurovascular leader heads for the exit  ~1 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, has announced his departure from the company....

JNJMarch 19, 2025FDA Clears Johnson & Johnson Robot for Enhanced Bronchoscopy  ~1 min.

Johnson & Johnson's MedTech division has received clearance from the FDA for its enhanced robotic-assisted bronchoscopy system....

JNJMarch 18, 2025Johnson & Johnson MedTech Introduces New EP Neurovascular Leader  ~1 min.

Johnson & Johnson MedTech, a subsidiary of Johnson & Johnson, has appointed a new leader for its electrophysiology and neurovascular group....

JNJMarch 14, 2025Johnson & Johnson's Decades-Long Quest for Effective IBD Treatments  ~1 min.

Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD)....

JNJFebruary 28, 2025Johnson & Johnson's Strong Performance Since Last Earnings Report Raises Expectations  ~1 min.

Johnson & Johnson (JNJ) has shown an impressive 8.9% increase in its stock price since the release of its last earnings report....

JNJFebruary 26, 2025The surgical devices I design for JJ speed healing and save lives  ~1 min.

Johnson & Johnson (JNJ) has been at the forefront of medical technology, constantly innovating and developing breakthrough surgical devices that not only speed up the healing process but also save lives....

JNJFebruary 18, 2025Johnson & Johnson reportedly wants to sell Cerenovus for 1B  ~1 min.

According to recent reports, Johnson & Johnson is considering selling its Cerenovus stroke business for 1 billion dollars....

JNJFebruary 16, 2025Johnson & Johnson Explores Sale of Cerenovus for $1 Billion  ~1 min.

According to reports, pharmaceutical giant Johnson & Johnson is looking to sell its stroke care business, Cerenovus, for a staggering $1 billion....

JNJMarch 21, 2025Johnson & Johnson Neurovascular leader heads for the exit  ~1 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, has announced his departure from the company....

JNJMarch 18, 2025Johnson & Johnson MedTech Introduces New EP Neurovascular Leader  ~1 min.

Johnson & Johnson MedTech, a subsidiary of Johnson & Johnson, has appointed a new leader for its electrophysiology and neurovascular group....

ETSYDecember 22, 2024Etsy Inc. Faces Controversy Over Request to Remove Israeli Jewish Descriptions  ~1 min.

Geode Capital Management LLC, a major shareholder of Etsy Inc., recently sold 946,105 shares of the company's stock. The sale was reported on the NASDAQ under the ticker symbol ETSY....

AZNDecember 31, 2024Investors Encouraged to Join Class Action Lawsuit Against AstraZeneca PLC  ~1 min.

Shareholders who have suffered financial losses with AstraZeneca PLC (AZN) are being urged to join a class-action lawsuit....

ESJanuary 13, 2025Eversource Energy Faces Controversy Over Electric Bills  ~1 min.

Eversource Energy, a leading electricity company, finds itself in the midst of controversy as regulators question the accuracy of their electric bills....